Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Wen Jiang · UT SOUTHWESTERN MEDICAL CENTER · 2020 · $253,377 — Project Summary Despite significant advances in the treatment of breast cancer, the metastatic form of the disease remains highly lethal, with a 5-year overall survival rate of only around 20%. Even with the use of new, targeted therapies such as antibodies against the human epidermal receptor 2 (H…
John T Chang · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2020 · $557,572 — Project Summary Mortality from infectious diseases remains a leading cause of death worldwide, making the development of new vaccines an important priority of biomedical research. Immunologic memory is a cardinal feature of adaptive immunity and an important goal of vaccination strategies. Traditio…
Isaac Jonathan Krauss · BRANDEIS UNIVERSITY · 2020 · $587,087 — Project Summary/Abstract Extensive study of HIV+ individuals in recent years has brought to light many examples of antibodies that can neutralize a broad range of HIV strains and protect against viral challenge in animal models of infection. The portion of viral surface most commonly targeted by suc…
Asok Antony · RLR VA MEDICAL CENTER · 2020 — Despite the advent of effective anti-Human Papillomavirus (HPV) vaccines, there are no biological agents to reliably prevent ~80 million Americans from transmitting their infectious HPV viral particles to sexual partners. Earlier we determined that the post-translational homocysteinylation of an mR…
Kristina De Paris · DUKE UNIVERSITY · 2020 · $1,307,799 — ABSTRACT – Overall Nearly 600,000 new HIV infections occur yearly in adolescents/young adults (ages 15-24 years), the only population in which HIV infections continue to rise. The end of the HIV/AIDS epidemic will be achievable only when an effective vaccine regimen can elicit long-term protective i…
Scott G Hansen · OREGON HEALTH & SCIENCE UNIVERSITY · 2020 · $1,146,291 — Project Summary With 36 million people currently living with HIV worldwide, developing a prophylactic HIV vaccine that protects against sexual transmission remains a top global health priority. A pre-clinical HIV vaccine approach based on strain 68-1 of rhesus cytomegalovirus expressing SIV antigens…
JOHN N GALGIANI · UNIVERSITY OF ARIZONA · 2020 · $563,465 — Project Summary Coccidioidomycosis (Valley Fever) is a serious public health problem for the Southwestern United States and all who visit there. A small proportion of infections result in progressive, debilitating, even life-threatening illness (disseminated coccidioidomycosis or DCM). All evidence …
JOHN H. SAMPSON · DUKE UNIVERSITY · 2020 · $584,463 — ABSTRACT We have previously reported in Nature that patients with newly-diagnosed glioblastoma (GBM) randomized to receiving vaccines against Cytomegalovirus (CMV) using a potent vaccine site preconditioning regimen had a statistically significant increase in progression-free survival (PFS) and over…
Rachel Fearns · BOSTON UNIVERSITY MEDICAL CAMPUS · 2020 · $534,809 — Marburg virus (MARV) belongs to the filovirus family and is highly pathogenic in humans. Despite being classified as Category A Priority Pathogen by NIAID, and its potential to cause large-scale outbreaks, similar to the recent Ebola virus outbreak, research on MARV lags significantly behind that on…
Daniel Pearce Depledge · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2020 · $545,420 — 7. PROJECT SUMMARY / ABSTRACT Chemical modification of mRNA provides a powerful means to dynamically alter gene expression in eukaryotes via epitranscriptomic changes. In particular, methylation of adenosine at the N6 position (m6A) constitutes the most widespread internal base modification to mRNA.…
Richard B Kennedy · MAYO CLINIC ROCHESTER · 2020 · $792,332 — ABSTRACT The broad long-term goal of this application is to identify innate and T helper (Th) cell transcriptomic signatures of immune response and further our understanding of sex-dependent human immune responses to two unique influenza A/H3N2 vaccines in a population of older adult males and femal…
Alison Whitney Ashbrook · ROCKEFELLER UNIVERSITY · 2020 · $69,306 — PROJECT SUMMARY/ABSTRACT Translation is a critical stage at which the abundance, timing, and localization of gene expression is regulated. In the case of infection, precise control of translational machinery and processes can determine whether an effective antiviral program is initiated or whether …
Paul Michael Armistead · UNIV OF NORTH CAROLINA CHAPEL HILL · 2020 · $450,736 — DESCRIPTION (provided by applicant): Chronic and acute leukemias are responsible for ~25,000 deaths annually in the US - a mortality rate that represents ~5% of all cancer related deaths. While leukemias are susceptible to antigen-specific T-cell mediated cytotoxicity, leukemia antigen (LA) di…
Clayton C Caswell · VIRGINIA POLYTECHNIC INST AND ST UNIV · 2020 · $195,705 — Project Summary Brucella spp. are bacteria that naturally infect a variety of domesticated and wild animals leading to abortions and sterility, and these bacteria are also capable of causing debilitating human infections, which often result from human exposure to infected animals and animal product…
JOSEPH M FOX · UNIVERSITY OF DELAWARE · 2020 · $315,259 — Project Summary The goal of this Center of Biomedical Research Excellence is to continue our efforts to develop molecular approaches for probing biology, to discover and apply new chemical biology tools for the study of biological pathways associated with disease, and to develop computational approa…
Jesse Hong-Sae Erasmus · UNIVERSITY OF WASHINGTON · 2020 · $44,294 — PROJECT SUMMARY Viral replicons, or self-replicating RNA elements incapable of initiating a spreading infection, are traditionally packaged into virus particles, termed viral replicon particles (VRPs), for in vivo delivery. Alternatively, they can be encoded on a plasmid DNA and transfected for host…
Brian Geiss · COLORADO STATE UNIVERSITY · 2020 · $407,060 — SARS-CoV-2 must cap and methylate its mRNAs to ensure their stability, translatability, and avoid detection by host innate immune mechanism as non-self transcripts. The process of RNA capping, therefore, is pivotal to the success of a SARS-CoV-2 infection. It also represents a key contributor to the…
David M Koelle · UNIVERSITY OF WASHINGTON · 2020 · $172,599 — Project Summary: The waning of immunity has a major impact on morbidity and mortality in the aged. Antigen-specific, acquired, and especially T-cellular is important in host defense against chronic intracellular pathogens and cancer. Infections with these microbes and skin cancers with high mutation…
Scott Eric Hensley · UNIVERSITY OF PENNSYLVANIA · 2020 · $807,420 — As early as 1960, Thomas Francis Jr. first noted that antibody responses to early childhood influenza virus infections are preferentially recalled later in life upon exposure to antigenically distinct viral strains. He coined the phrase ‘original antigenic sin’ to describe this phenomena. We recentl…
Henry Charles Mwandumba · CORNELL UNIVERSITY · 2020 · $676,988 — Our recent advances in the use of fluorescent fitness reporter Mtb strains in the murine TB model has afforded us a unique appreciation of the role of macrophage lineages in both the control and promotion of Mtb growth. Moreover, the extension of these observations through the successful development…